November 23, 2021
2 min watch
Save
VIDEO: Biomarkers for RA-ILD may soon ‘be in the hands of clinicians’
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Jeffrey A. Sparks, MD, MMSc, highlights a study from ACR Convergence 2021 that assessed biomarker predictors of rheumatoid arthritis-associated interstitial lung disease.
“Certainly, this is something that I think might be in the hands of clinicians in the relatively near future to help understand who to screen and predict for RA-ILD,” said Sparks, associate physician at Brigham and Women's Hospital.
Reference
- England BR, et al. Abstract 1916. Presented at: ACR Convergence 2021; November 3-10, 2021 (virtual meeting).
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Sparks reports financial disclosures with AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, Inova Diagnostics, Janssen, Musculoskeletal and Skin Diseases, National Institute of Arthritis, Optum, Pfizer and R. Bruce and Joan M. Mickey Research Scholar Fund.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.